Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer
BACKGROUND: Abiraterone acetate is an effective drug for castration-resistant prostate cancer, but cardiac serious adverse events (SAEs) may occur. We studied their association with N-terminal pro–brain natriuretic peptide (NT-proBNP) and troponin T (TnT) during abiraterone therapy. PATIENTS AND MET...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-12-01
|
| Series: | Translational Oncology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523316300365 |
| _version_ | 1818984375755210752 |
|---|---|
| author | Sara Campora Eleonora Campazzi Silvia Zanardi Matteo Puntoni Marco Piccininno Arnoldo Piccardo Mehrdad Shoushtari Zadeh Naseri Carlotta Defferrari Nicoletta Provinciali Marilena Petrera Domenico Marra Ennio Biscaldi Gian Carlo Antonucci Damiano Ricci Matteo Clavarezza Alessandra Gennari Alberto Gozza Mauro D'Amico Marco Mori Andrea DeCensi |
| author_facet | Sara Campora Eleonora Campazzi Silvia Zanardi Matteo Puntoni Marco Piccininno Arnoldo Piccardo Mehrdad Shoushtari Zadeh Naseri Carlotta Defferrari Nicoletta Provinciali Marilena Petrera Domenico Marra Ennio Biscaldi Gian Carlo Antonucci Damiano Ricci Matteo Clavarezza Alessandra Gennari Alberto Gozza Mauro D'Amico Marco Mori Andrea DeCensi |
| author_sort | Sara Campora |
| collection | DOAJ |
| description | BACKGROUND: Abiraterone acetate is an effective drug for castration-resistant prostate cancer, but cardiac serious adverse events (SAEs) may occur. We studied their association with N-terminal pro–brain natriuretic peptide (NT-proBNP) and troponin T (TnT) during abiraterone therapy. PATIENTS AND METHODS: In a single institution, 17 patients were treated with abiraterone acetate 1 g daily with concomitant prednisone and then switched to dexametasone plus canrenone. Blood samples for PSA, NT-proBNP, and TnT were obtained at baseline and after 1, 3, and 6 months. RESULTS: Five patients (29.4%) experienced G3 to 4 cardiac SAEs after a median of 13 weeks (range, 9-32), including pulmonary edema, heart failure, acute coronary syndrome, sinus bradycardia with syncope, and pulmonary edema. At baseline, 4 weeks, and 3 months, median NT-proBNP and TnT levels were higher in patients with subsequent cardiac SAEs (P= .03 and P= .04 for NT-proBNP and TnT at 3 months, respectively). After switching to dexametasone and introducing canrenone, no additional cardiac SAEs were noted. Overall response rate was 67%. CONCLUSIONS: Our study suggests a higher than expected risk of cardiac SAEs during abiraterone treatment which may well be due to the small sample size and the unrestricted entry criteria. However, baseline and frequent NT-proBNP and TnT monitoring predicted a higher risk for cardiac SAE. Larger studies should confirm our findings. |
| first_indexed | 2024-12-20T18:18:01Z |
| format | Article |
| id | doaj.art-a326b50ed2914cb189e7ba0ca4b1fbeb |
| institution | Directory Open Access Journal |
| issn | 1936-5233 1944-7124 |
| language | English |
| last_indexed | 2024-12-20T18:18:01Z |
| publishDate | 2016-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj.art-a326b50ed2914cb189e7ba0ca4b1fbeb2022-12-21T19:30:20ZengElsevierTranslational Oncology1936-52331944-71242016-12-019660060510.1016/j.tranon.2016.08.001Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate CancerSara Campora0Eleonora Campazzi1Silvia Zanardi2Matteo Puntoni3Marco Piccininno4Arnoldo Piccardo5Mehrdad Shoushtari Zadeh Naseri6Carlotta Defferrari7Nicoletta Provinciali8Marilena Petrera9Domenico Marra10Ennio Biscaldi11Gian Carlo Antonucci12Damiano Ricci13Matteo Clavarezza14Alessandra Gennari15Alberto Gozza16Mauro D'Amico17Marco Mori18Andrea DeCensi19Units of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyUnits of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyUnits of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyClinical Trial/Scientific Direction, E.O. Ospedali Galliera, Genova, ItalyCardiology, E.O. Ospedali Galliera, Genova, ItalyNuclear Medicine, E.O. Ospedali Galliera, Genova, ItalyNuclear Medicine, E.O. Ospedali Galliera, Genova, ItalyUnits of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyUnits of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyUnits of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyUnits of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyRadiology, E.O. Ospedali Galliera, Genova, ItalyCritical Care Medicine, E.O. Ospedali Galliera, Genova, ItalyCardiology, E.O. Ospedali Galliera, Genova, ItalyUnits of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyUnits of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyUnits of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyUnits of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyLaboratory Analysis, E.O. Ospedali Galliera, Genova, ItalyUnits of Medical Oncology, E.O. Ospedali Galliera, Genova, ItalyBACKGROUND: Abiraterone acetate is an effective drug for castration-resistant prostate cancer, but cardiac serious adverse events (SAEs) may occur. We studied their association with N-terminal pro–brain natriuretic peptide (NT-proBNP) and troponin T (TnT) during abiraterone therapy. PATIENTS AND METHODS: In a single institution, 17 patients were treated with abiraterone acetate 1 g daily with concomitant prednisone and then switched to dexametasone plus canrenone. Blood samples for PSA, NT-proBNP, and TnT were obtained at baseline and after 1, 3, and 6 months. RESULTS: Five patients (29.4%) experienced G3 to 4 cardiac SAEs after a median of 13 weeks (range, 9-32), including pulmonary edema, heart failure, acute coronary syndrome, sinus bradycardia with syncope, and pulmonary edema. At baseline, 4 weeks, and 3 months, median NT-proBNP and TnT levels were higher in patients with subsequent cardiac SAEs (P= .03 and P= .04 for NT-proBNP and TnT at 3 months, respectively). After switching to dexametasone and introducing canrenone, no additional cardiac SAEs were noted. Overall response rate was 67%. CONCLUSIONS: Our study suggests a higher than expected risk of cardiac SAEs during abiraterone treatment which may well be due to the small sample size and the unrestricted entry criteria. However, baseline and frequent NT-proBNP and TnT monitoring predicted a higher risk for cardiac SAE. Larger studies should confirm our findings.http://www.sciencedirect.com/science/article/pii/S1936523316300365 |
| spellingShingle | Sara Campora Eleonora Campazzi Silvia Zanardi Matteo Puntoni Marco Piccininno Arnoldo Piccardo Mehrdad Shoushtari Zadeh Naseri Carlotta Defferrari Nicoletta Provinciali Marilena Petrera Domenico Marra Ennio Biscaldi Gian Carlo Antonucci Damiano Ricci Matteo Clavarezza Alessandra Gennari Alberto Gozza Mauro D'Amico Marco Mori Andrea DeCensi Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer Translational Oncology |
| title | Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer |
| title_full | Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer |
| title_fullStr | Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer |
| title_full_unstemmed | Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer |
| title_short | Association of Biomarkers with Serious Cardiac Adverse Events during Abiraterone Acetate Treatment in Castration Resistant Prostate Cancer |
| title_sort | association of biomarkers with serious cardiac adverse events during abiraterone acetate treatment in castration resistant prostate cancer |
| url | http://www.sciencedirect.com/science/article/pii/S1936523316300365 |
| work_keys_str_mv | AT saracampora associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT eleonoracampazzi associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT silviazanardi associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT matteopuntoni associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT marcopiccininno associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT arnoldopiccardo associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT mehrdadshoushtarizadehnaseri associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT carlottadefferrari associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT nicolettaprovinciali associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT marilenapetrera associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT domenicomarra associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT enniobiscaldi associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT giancarloantonucci associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT damianoricci associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT matteoclavarezza associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT alessandragennari associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT albertogozza associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT maurodamico associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT marcomori associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer AT andreadecensi associationofbiomarkerswithseriouscardiacadverseeventsduringabirateroneacetatetreatmentincastrationresistantprostatecancer |